论文部分内容阅读
目的 :观察以异长春花碱加顺铂方案化疗联合胸部放疗综合治疗不可切除的晚期非小细胞肺癌的临床疗效及毒副作用。方法 :31例晚期非小细胞肺癌患者接受异长春花碱加顺铂方案化疗联合胸部放疗 (放化疗组 ) ,与同期单纯接受化疗的 32例 (化疗组 )对比。结果 :近期客观有效率 ,中位生存期和 1年、2年、3年生存率 :放化疗组分别为 5 1 6 % ,13个月和5 2 8%、2 8 8%、17 2 % ;而化疗组则为 4 6 9% ,12个月和 4 5 6 %、19 8%、7 1% ,两组无显著差别 (P >0 0 5 )。但近期有效者 ,放化疗组的中位生存期为 17个月 ,而化疗组则为 12个月 ,放化疗组显著高于化疗组 (P <0 0 5 )。毒副作用可耐受 ,无治疗相关性死亡。结论 :以异长春花碱加顺铂方案化疗联合胸部放疗治疗不可切除的晚期非小细胞肺癌有效安全。与同期单纯接受化疗的对照组相比 ,两组疗效无显著差异 ,但近期有效者例外。
OBJECTIVE: To observe the clinical efficacy and side effects of the combination chemotherapy of vinorelbine plus cisplatin and thoracic radiotherapy in the treatment of unresectable non-small cell lung cancer. Methods: Totally 31 patients with advanced non-small cell lung cancer received chemotherapy with isoflavone and cisplatin combined with chest radiotherapy (radiotherapy and chemotherapy group), compared with 32 patients receiving chemotherapy alone in the same period (chemotherapy group). Results: The recent objective and effective rates, median survival and 1, 2 and 3-year survival rates were 51.6%, 13 months and 52.8%, 28.8% and 17.2% respectively in radiotherapy and chemotherapy groups While the chemotherapy group was 46.9%, 12 months and 45.6%, 19.8% and 71.1% respectively, with no significant difference between the two groups (P> 0.05). However, the median effective life expectancy of radiotherapy and chemotherapy group was 17 months, while that of chemotherapy group was 12 months. The radiotherapy and chemotherapy group was significantly higher than that of chemotherapy group (P <0.05). Toxic side effects can be tolerated without treatment-related deaths. CONCLUSION: It is effective and safe to treat unresectable advanced non-small cell lung cancer with vincristine plus cisplatin regimen combined with chest radiotherapy. There was no significant difference in efficacy between the two groups when compared with the control group receiving chemotherapy alone during the same period, with the exception of the most recent ones.